Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.52 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10911056 | 0.93 | NPC1 (0.59) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL3822090 | 0.89 | NPC1 (0.60) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL2302774 | 0.84 | NPC1 (0.64) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL27563323 | 0.83 | NPC1 (0.59) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL6378992 | 0.82 | NPC1 (0.62) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL19133492 | 0.82 | NPC1 (0.67) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL7393206 | 0.82 | POLB (0.66) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL4768363 | 0.81 | NPC1 (0.66) | NPC1RAB9AKMT2APOLBHDAC6 | |
| SCHEMBL24386079 | 0.81 | L3MBTL1 (0.71) | NPC1RAB9AKMT2AMEN1HDAC6 | |
| SCHEMBL7214981 | 0.81 | NPC1 (0.60) | NPC1RAB9AKMT2APOLBHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0646110-B1 | N-SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS | BASF AG (DE) | 1996-10-23 | — | — | EP | disclosed |
| US-5521209-A | N-substituted azabicyclo[3.2.0]heptane derivatives as neuroleptics, the preparation and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 1996-05-28 | — | — | US | disclosed |
| EP-0646110-A1 | N-SUBSTITUED 3-AZABICYCLO 3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS ETC. | BASF AG (DE) | 1995-04-05 | — | — | EP | disclosed |
| WO-1994000431-A1 | N-SUBSTITUED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS ETC. | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |
| EP-0104614-B1 | PHENYLPIPERAZINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 1986-12-30 | — | — | EP | disclosed |
| US-4560686-A | Method for treating circulatory diseases by using (2-lower alkoxyphenyl)piperazine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1985-12-24 | — | — | US | disclosed |
| EP-0104614-A1 | Phenylpiperazine derivatives and process for producing the same | Chugai Seiyaku Kabushiki Kaisha (JP) | 1984-04-04 | — | — | EP | disclosed |